What we're reading, October 27, 2015: a much-improved Healthcare.gov website, report says drug prices rose at a much slower rate in 2015, and USPSTF recommends glucose testing in asymptomatic adults who are overweight or obese.
Newly Remodeled HealthCare.gov Site More User Friendly
The new website, reports The New York Times, has worked as the government promised, during the third open enrollment season. A new feature this year is a cost calculator that helps would-be enrollees compare different health plans based on their estimate of low, medium, of high use of medical services in 2016, though it does not let users sort plans based on total costs.
Read more here: http://nyti.ms/1k73ejo.
2015 Sees a More Gradual Slope to Prescription Drug Prices
A new analysis by the healthcare technology firm Truveris, reports that prescription drug prices rose 9.1% through September 30, 2015, for all medicines, compared with 10.9% seen in 2014. This information is based on the company’s analysis of claims data that included more than 300 million prescription payments to US pharmacies. The claims data does not account for drug rebates, coupons, or copay cards.
Read more here: http://bit.ly/208u4bH.
USPSTF Recommends Screening for Glucose and T2DM in Overweight and Obese Adults
The U.S. Preventive Services Task Force (USPSTF), as part of cardiovascular risk assessment in obese and overweight adults 40 to 70 years of age, has recommended screening for blood glucose levels. Additionally, the USPSTF recommendation urges physicians to refer patients with abnormal glucose levels to behavior counseling to ensure a healthy diet and incorporating physical activity in their daily life.
Read the paper published in the Annals of Internal Medicine here: http://bit.ly/1N38TCJ.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More